

02-15-02

PATENT



UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

February 13, 2002

Date of Deposit

Anne M. Hines

Signature

EL 916210871 US

Express Mail No

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231
Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: F15026 US PCT
INVENTORS: Begon, et al.
TITLE: PROCESS FOR PRODUCING FINE MEDICINAL SUBSTANCES

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	Total Pages	13
2. <input checked="" type="checkbox"/> Specification (preferred arrangement set forth below)		
- Descriptive title of the Invention		
- Cross References to Related Applications		
- Statement Regarding Fed sponsored R & D		
- Reference to Microfiche Appendix		
- Background of the Invention		
- Brief Summary of the Invention		
- Brief Description of the Drawings (if filed)		
- Detailed Description		
- Claim(s)		
- Abstract of the Disclosure		
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113)	Total Sheets	1
4. Oath or Declaration	Total Pages	2
a. <input checked="" type="checkbox"/> Newly unexecuted (original or copy)		
b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d)) (for continuation/divisional with Box 16 completed)		
i. <input type="checkbox"/> DELETION OF INVENTOR(S)		
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. <input type="checkbox"/> Microfiche Computer Program (Appendix)		
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)		
a. <input type="checkbox"/> Computer Readable Copy		
b. <input type="checkbox"/> Paper Copy (identical to computer copy)		
c. <input type="checkbox"/> Statement verifying identity of above copies		

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part
of prior application no: PCT/GB00/03178, filed August 18, 2000,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of Great Britain Application No. 9919693.3, filed August 19, 1999. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement Power of
(*when there is an assignee*) Attorney
9. English Translation Document (*if applicable*)
10. Information Disclosure Copies of IDS
Statement (IDS)/PTO-1449 Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
15. Other: Print EFS

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


Ronald G. Ört, Reg. No. 26,969
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Mail Code: EMC-G1
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

Aventis Docket No. FI5026 US PCT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2002

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** **(S) 740.00****Complete if Known**

Application Number	Not Yet Assigned
Filing Date	February 13, 2002
First Named Inventor	Begon
Examiner Name	
Group / Art Unit	
Attorney Docket No.	FI5026 US PCT

METHOD OF PAYMENT (check all that apply)
 Check Credit Card Money Other None
 Order
 Deposit AccountDeposit Account Number **18-1982**Depositor/Account Name **Aventis Pharmaceuticals Inc.**

The Commissioner is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account
FEES CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee	Fee	Fee	Fee	Fee Description	Fee Paid
Fee Code	Fee Code	(\\$)	Fee Code	Fee	(\\$)		
101	740	201	370	Utility filing fee	740		
106	330	206	165	Design filing fee			
107	510	207	255	Plant filing fee			
108	740	206	370	Reissue filing fee			
114	160	214	80	Provisional filing fee			
SUBTOTAL (1)		(S)740.00					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total	18	-20** = 0	x 0	= 0
Independent	1	- 3** = 0	x 0	= 0
Claims				
Multiple Dependent		0	= 0	


Large Entity	Small Entity	Fee	Fee	Fee	Fee Description	
Fee Code	Fee Code	(\\$)	Fee Code	Fee	(\\$)	
103	18	203	9	Claims in excess of 20		
102	84	202	42	Independent claims in excess of 3		
104	280	204	140	Multiple dependent claim, if not paid		
109	84	209	42	**Reissue independent claims over original patent		
110	18	210	9	**Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2)		(S)0.00				

*or number previously paid, if greater; For Reissues, see above

FEES CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee	Fee	Fee	Fee Description	Fee Paid
Fee Code	Fee Code	(\\$)	Fee Code	Fee	(\\$)	
105	130	205	65	Surcharge - late filing fee or oath		
127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
139	130	139	130	Non-English Specification		
147	2,520	147	2,520	For filing a request for reexamination		
112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
115	110	215	55	Extension for reply within first month		
116	400	216	200	Extension for reply within second month		
117	920	217	460	Extension for reply within third month		
118	1,440	218	720	Extension for reply within fourth month		
128	1,960	228	980	Extension for reply within fifth month		
119	320	219	160	Notice of Appeal		
120	320	220	160	Filing a brief in support of an appeal		
121	200	221	140	Request for oral hearing		
138	1,510	138	1,510	Petition to institute a public use proceeding		
140	110	240	55	Petition to revive - unavoidable		
141	1,280	241	640	Petition to revive - unintentional		
142	1,280	242	640	Utility issue fee (or reissue)		
143	460	243	230	Design issue fee		
144	620	244	310	Plant issue fee		
122	130	122	130	Petitions to the Commissioner		
123	50	123	50	Petitions related to provisional applications		
126	180	126	180	Submission of Information Disclosure Stmt		
581	40	581	40	Recording each patent assignment per property (times number of properties)		
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))		
179	740	279	370	Request for Continued Examination (RCE)		
169	900	169	900	Request for expedited examination of a design application		
Other fee (specify)						
*Reduced by Basic Filing Fee Paid						
						SUBTOTAL (3) (S)

SUBMITTED BY

Name (Print/Type)	Ronald G. Ort, Reg. No. 26,969	Registration No. (Attorney/Agent)	26,969	Telephone	(908) 231-4656
Signature				Date	February 13, 2002

Complete (If applicable)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Aventis Pharmaceuticals Inc. template